Atovaquone-Proguanil

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D224D0005

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Sinnar, INDIA

SourceSAM
Documents4
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the contract titled "Atovaquone-Proguanil," identified by procurement number SPE2D224D0005. This contract pertains to the manufacturing and supply of pharmaceutical preparations, specifically Atovaquone, as indicated by the NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and product service code 6505. The contract is structured with option years, and recent modifications have been made to exercise these options. Modification P00001 activates Option Year 1, effective from April 4, 2025, through April 3, 2026, while Modification P00003 exercises Option Year 2, covering the period from April 4, 2026, to April 3, 2027. Additionally, Modification P00002 has been updated in accordance with DoD Class Deviation 2025-O0003, reflecting compliance with specific Department of Defense procurement regulations. The place of performance for this contract is Sinnar, India, which underscores the global sourcing aspect of the pharmaceutical supply chain for the U.S. military. The contract is managed by DLA Troop Support, a federal office responsible for ensuring the availability of critical medical supplies to support military operations. Key objectives of this procurement include the reliable production and delivery of Atovaquone-Proguanil, a medication essential for troop health and readiness. The expected deliverables are consistent with pharmaceutical manufacturing standards, ensuring quality and timely supply throughout the contract lifecycle. For contractors interested in this opportunity, the primary points of contact are Kyle Lewicki ([email protected], 4457370977) and Jason Wray ([email protected], 4457376304). The notice remains active as of April 3, 2026, and further details, including attachments, can be accessed via the official SAM.gov listing at https://sam.gov/opp/f1abaa8c7320409b8fe6460265139052/view. This contract represents a stable, multi-year opportunity for pharmaceutical manufacturers with capabilities in producing Atovaquone-Proguanil and meeting rigorous Department of Defense requirements. The scope and requirements are expected to remain consistent throughout the contract period, focusing on quality, compliance, and timely delivery to support U.S. military needs.